Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT00068952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy
Study identification
- NCT ID
- NCT00068952
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Interventions
- Carmustine (BCNU) Drug
- Edotecarin Drug
- Lomustine (CCNU) Drug
- Temozolomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2003
- Primary completion
- Not listed
- Completion
- Feb 28, 2006
- Last update posted
- Mar 31, 2008
2003 – 2006
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | — | — |
| Pfizer Investigational Site | Little Rock | Arkansas | — | — |
| Pfizer Investigational Site | New Haven | Connecticut | — | — |
| Pfizer Investigational Site | Orlando | Florida | — | — |
| Pfizer Investigational Site | Atlanta | Georgia | — | — |
| Pfizer Investigational Site | Chicago | Illinois | — | — |
| Pfizer Investigational Site | Evanston | Illinois | — | — |
| Pfizer Investigational Site | Edgewood | Kentucky | — | — |
| Pfizer Investigational Site | Edgweood | Kentucky | — | — |
| Pfizer Investigational Site | Lexington | Kentucky | — | — |
| Pfizer Investigational Site | Boston | Massachusetts | — | — |
| Pfizer Investigational Site | Lebanon | New Hampshire | — | — |
| Pfizer Investigational Site | Edison | New Jersey | — | — |
| Pfizer Investigational Site | Summit | New Jersey | — | — |
| Pfizer Investigational Site | Cincinnati | Ohio | — | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | — | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | Charlottesville | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00068952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2008 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00068952 live on ClinicalTrials.gov.